Affymax Receives $10M Milestone Payment for FDA Filing of New Drug Application for Hematide/Peginesatide

Affymax, Inc. AFFY today announced that it has received a $10 million development milestone payment from Takeda Pharmaceutical Company as part of the companies' exclusive global agreement to develop and commercialize peginesatide, Affymax's investigational drug for the treatment of anemia in chronic renal failure patients. The payments were triggered by the acceptance and filing of the New Drug Application for peginesatide by the FDA.